Global Nanomedicine
Global Nanomedicine

Nanomedicine Comprehensive Study by Type (Liposomes, Micelles, Nanocrystals, Polymeric Nanoparticles, Metallic Nanoparticles, Mesoporous Silica Nanoparticles, Others), Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Implants, Others), End Users (Hospitals, Ambulatory Surgical Centre, Clinics, Specialised Drug R&D Institutes, Managed Care Organizations), Modality (Diagnostics, Treatments) Players and Region - Global Market Outlook to 2024

Nanomedicine Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 214 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Nanomedicine is treatment of diseases, injuries or pain by usage of molecular tools. It is made by application of nano technology and used for the prevention of diseases. The size of nanomaterial is similar to biological molecules and can easily target the difficult to reach sites. It can provide same results in smaller dose as conventional counterparts. Additionally, the decreased size causes the surface area to volume ratio to rise which is suitable for the chemical interaction with biomolecules. There is wide applications of nanomedicine in medical diagnostics

The market study is being classified by Type (Liposomes, Micelles, Nanocrystals, Polymeric Nanoparticles, Metallic Nanoparticles, Mesoporous Silica Nanoparticles and Others), by Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Implants and Others) and major geographies with country level break-up.

GE Healthcare (United States), Johnson & Johnson (United States), Mallinckrodt plc (United Kingdom), Merck & Co. Inc. (United States), Nanosphere Inc. (United States), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), UCB (Union chimique belge) S.A (Belgium), Nanobiotix (France) and Nanomedical systems (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sigma-Tau Pharmaceuticals Inc. (United Kingdom), Smith & Nephew PLC (United Kingdom) and Stryker Corp (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Nanomedicine market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Nanomedicine market by Type, Application and Region.

On the basis of geography, the market of Nanomedicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Usage of Injectable Nano Medicine
  • Growing Need of Therapies with Lesser Side Effects

Market Trend
  • Increasing Adoption of Nanomedicine in Multiple Applications
  • Introduction of Innovative Technologies for Drug Deliveries

Restraints
  • Increasing Availability of Generics in Developing and Developed Countries
  • Long Approvals Associated with the Nanomedicien

Opportunities
  • Rising Initiatives by Government for Health Care


Market Leaders and their expansionary development strategies
In 2019, Johnson and Johnson has acquired Auris Health Inc which will help to solve the unmet clinical needs



Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Liposomes
  • Micelles
  • Nanocrystals
  • Polymeric Nanoparticles
  • Metallic Nanoparticles
  • Mesoporous Silica Nanoparticles
  • Others
By Application
  • Drug Delivery
  • Vaccines
  • Diagnostic Imaging
  • Regenerative Medicine
  • Implants
  • Others
By End Users
  • Hospitals
  • Ambulatory Surgical Centre
  • Clinics
  • Specialised Drug R&D Institutes
  • Managed Care Organizations

By Modality
  • Diagnostics
  • Treatments

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Usage of Injectable Nano Medicine
      • 3.2.2. Growing Need of Therapies with Lesser Side Effects
    • 3.3. Market Trends
      • 3.3.1. Increasing Adoption of Nanomedicine in Multiple Applications
      • 3.3.2. Introduction of Innovative Technologies for Drug Deliveries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nanomedicine, by Type, Application, End Users, Modality and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Nanomedicine (Value)
      • 5.2.1. Global Nanomedicine by: Type (Value)
        • 5.2.1.1. Liposomes
        • 5.2.1.2. Micelles
        • 5.2.1.3. Nanocrystals
        • 5.2.1.4. Polymeric Nanoparticles
        • 5.2.1.5. Metallic Nanoparticles
        • 5.2.1.6. Mesoporous Silica Nanoparticles
        • 5.2.1.7. Others
      • 5.2.2. Global Nanomedicine by: Application (Value)
        • 5.2.2.1. Drug Delivery
        • 5.2.2.2. Vaccines
        • 5.2.2.3. Diagnostic Imaging
        • 5.2.2.4. Regenerative Medicine
        • 5.2.2.5. Implants
        • 5.2.2.6. Others
      • 5.2.3. Global Nanomedicine by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centre
        • 5.2.3.3. Clinics
        • 5.2.3.4. Specialised Drug R&D Institutes
        • 5.2.3.5. Managed Care Organizations
      • 5.2.4. Global Nanomedicine by: Modality (Value)
        • 5.2.4.1. Diagnostics
        • 5.2.4.2. Treatments
      • 5.2.5. Global Nanomedicine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Nanomedicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GE Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mallinckrodt plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nanosphere Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. UCB (Union chimique belge) S.A (Belgium)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Nanobiotix (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Nanomedical systems (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nanomedicine Sale, by Type, Application, End Users, Modality and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Nanomedicine (Value)
      • 7.2.1. Global Nanomedicine by: Type (Value)
        • 7.2.1.1. Liposomes
        • 7.2.1.2. Micelles
        • 7.2.1.3. Nanocrystals
        • 7.2.1.4. Polymeric Nanoparticles
        • 7.2.1.5. Metallic Nanoparticles
        • 7.2.1.6. Mesoporous Silica Nanoparticles
        • 7.2.1.7. Others
      • 7.2.2. Global Nanomedicine by: Application (Value)
        • 7.2.2.1. Drug Delivery
        • 7.2.2.2. Vaccines
        • 7.2.2.3. Diagnostic Imaging
        • 7.2.2.4. Regenerative Medicine
        • 7.2.2.5. Implants
        • 7.2.2.6. Others
      • 7.2.3. Global Nanomedicine by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centre
        • 7.2.3.3. Clinics
        • 7.2.3.4. Specialised Drug R&D Institutes
        • 7.2.3.5. Managed Care Organizations
      • 7.2.4. Global Nanomedicine by: Modality (Value)
        • 7.2.4.1. Diagnostics
        • 7.2.4.2. Treatments
      • 7.2.5. Global Nanomedicine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nanomedicine: by Type(USD Million)
  • Table 2. Nanomedicine Liposomes , by Region USD Million (2013-2018)
  • Table 3. Nanomedicine Micelles , by Region USD Million (2013-2018)
  • Table 4. Nanomedicine Nanocrystals , by Region USD Million (2013-2018)
  • Table 5. Nanomedicine Polymeric Nanoparticles , by Region USD Million (2013-2018)
  • Table 6. Nanomedicine Metallic Nanoparticles , by Region USD Million (2013-2018)
  • Table 7. Nanomedicine Mesoporous Silica Nanoparticles , by Region USD Million (2013-2018)
  • Table 8. Nanomedicine Others , by Region USD Million (2013-2018)
  • Table 9. Nanomedicine: by Application(USD Million)
  • Table 10. Nanomedicine Drug Delivery , by Region USD Million (2013-2018)
  • Table 11. Nanomedicine Vaccines , by Region USD Million (2013-2018)
  • Table 12. Nanomedicine Diagnostic Imaging , by Region USD Million (2013-2018)
  • Table 13. Nanomedicine Regenerative Medicine , by Region USD Million (2013-2018)
  • Table 14. Nanomedicine Implants , by Region USD Million (2013-2018)
  • Table 15. Nanomedicine Others , by Region USD Million (2013-2018)
  • Table 16. Nanomedicine: by End Users(USD Million)
  • Table 17. Nanomedicine Hospitals , by Region USD Million (2013-2018)
  • Table 18. Nanomedicine Ambulatory Surgical Centre , by Region USD Million (2013-2018)
  • Table 19. Nanomedicine Clinics , by Region USD Million (2013-2018)
  • Table 20. Nanomedicine Specialised Drug R&D Institutes , by Region USD Million (2013-2018)
  • Table 21. Nanomedicine Managed Care Organizations , by Region USD Million (2013-2018)
  • Table 22. Nanomedicine: by Modality(USD Million)
  • Table 23. Nanomedicine Diagnostics , by Region USD Million (2013-2018)
  • Table 24. Nanomedicine Treatments , by Region USD Million (2013-2018)
  • Table 25. South America Nanomedicine, by Country USD Million (2013-2018)
  • Table 26. South America Nanomedicine, by Type USD Million (2013-2018)
  • Table 27. South America Nanomedicine, by Application USD Million (2013-2018)
  • Table 28. South America Nanomedicine, by End Users USD Million (2013-2018)
  • Table 29. South America Nanomedicine, by Modality USD Million (2013-2018)
  • Table 30. Brazil Nanomedicine, by Type USD Million (2013-2018)
  • Table 31. Brazil Nanomedicine, by Application USD Million (2013-2018)
  • Table 32. Brazil Nanomedicine, by End Users USD Million (2013-2018)
  • Table 33. Brazil Nanomedicine, by Modality USD Million (2013-2018)
  • Table 34. Argentina Nanomedicine, by Type USD Million (2013-2018)
  • Table 35. Argentina Nanomedicine, by Application USD Million (2013-2018)
  • Table 36. Argentina Nanomedicine, by End Users USD Million (2013-2018)
  • Table 37. Argentina Nanomedicine, by Modality USD Million (2013-2018)
  • Table 38. Rest of South America Nanomedicine, by Type USD Million (2013-2018)
  • Table 39. Rest of South America Nanomedicine, by Application USD Million (2013-2018)
  • Table 40. Rest of South America Nanomedicine, by End Users USD Million (2013-2018)
  • Table 41. Rest of South America Nanomedicine, by Modality USD Million (2013-2018)
  • Table 42. Asia Pacific Nanomedicine, by Country USD Million (2013-2018)
  • Table 43. Asia Pacific Nanomedicine, by Type USD Million (2013-2018)
  • Table 44. Asia Pacific Nanomedicine, by Application USD Million (2013-2018)
  • Table 45. Asia Pacific Nanomedicine, by End Users USD Million (2013-2018)
  • Table 46. Asia Pacific Nanomedicine, by Modality USD Million (2013-2018)
  • Table 47. China Nanomedicine, by Type USD Million (2013-2018)
  • Table 48. China Nanomedicine, by Application USD Million (2013-2018)
  • Table 49. China Nanomedicine, by End Users USD Million (2013-2018)
  • Table 50. China Nanomedicine, by Modality USD Million (2013-2018)
  • Table 51. Japan Nanomedicine, by Type USD Million (2013-2018)
  • Table 52. Japan Nanomedicine, by Application USD Million (2013-2018)
  • Table 53. Japan Nanomedicine, by End Users USD Million (2013-2018)
  • Table 54. Japan Nanomedicine, by Modality USD Million (2013-2018)
  • Table 55. India Nanomedicine, by Type USD Million (2013-2018)
  • Table 56. India Nanomedicine, by Application USD Million (2013-2018)
  • Table 57. India Nanomedicine, by End Users USD Million (2013-2018)
  • Table 58. India Nanomedicine, by Modality USD Million (2013-2018)
  • Table 59. South Korea Nanomedicine, by Type USD Million (2013-2018)
  • Table 60. South Korea Nanomedicine, by Application USD Million (2013-2018)
  • Table 61. South Korea Nanomedicine, by End Users USD Million (2013-2018)
  • Table 62. South Korea Nanomedicine, by Modality USD Million (2013-2018)
  • Table 63. Taiwan Nanomedicine, by Type USD Million (2013-2018)
  • Table 64. Taiwan Nanomedicine, by Application USD Million (2013-2018)
  • Table 65. Taiwan Nanomedicine, by End Users USD Million (2013-2018)
  • Table 66. Taiwan Nanomedicine, by Modality USD Million (2013-2018)
  • Table 67. Australia Nanomedicine, by Type USD Million (2013-2018)
  • Table 68. Australia Nanomedicine, by Application USD Million (2013-2018)
  • Table 69. Australia Nanomedicine, by End Users USD Million (2013-2018)
  • Table 70. Australia Nanomedicine, by Modality USD Million (2013-2018)
  • Table 71. Rest of Asia-Pacific Nanomedicine, by Type USD Million (2013-2018)
  • Table 72. Rest of Asia-Pacific Nanomedicine, by Application USD Million (2013-2018)
  • Table 73. Rest of Asia-Pacific Nanomedicine, by End Users USD Million (2013-2018)
  • Table 74. Rest of Asia-Pacific Nanomedicine, by Modality USD Million (2013-2018)
  • Table 75. Europe Nanomedicine, by Country USD Million (2013-2018)
  • Table 76. Europe Nanomedicine, by Type USD Million (2013-2018)
  • Table 77. Europe Nanomedicine, by Application USD Million (2013-2018)
  • Table 78. Europe Nanomedicine, by End Users USD Million (2013-2018)
  • Table 79. Europe Nanomedicine, by Modality USD Million (2013-2018)
  • Table 80. Germany Nanomedicine, by Type USD Million (2013-2018)
  • Table 81. Germany Nanomedicine, by Application USD Million (2013-2018)
  • Table 82. Germany Nanomedicine, by End Users USD Million (2013-2018)
  • Table 83. Germany Nanomedicine, by Modality USD Million (2013-2018)
  • Table 84. France Nanomedicine, by Type USD Million (2013-2018)
  • Table 85. France Nanomedicine, by Application USD Million (2013-2018)
  • Table 86. France Nanomedicine, by End Users USD Million (2013-2018)
  • Table 87. France Nanomedicine, by Modality USD Million (2013-2018)
  • Table 88. Italy Nanomedicine, by Type USD Million (2013-2018)
  • Table 89. Italy Nanomedicine, by Application USD Million (2013-2018)
  • Table 90. Italy Nanomedicine, by End Users USD Million (2013-2018)
  • Table 91. Italy Nanomedicine, by Modality USD Million (2013-2018)
  • Table 92. United Kingdom Nanomedicine, by Type USD Million (2013-2018)
  • Table 93. United Kingdom Nanomedicine, by Application USD Million (2013-2018)
  • Table 94. United Kingdom Nanomedicine, by End Users USD Million (2013-2018)
  • Table 95. United Kingdom Nanomedicine, by Modality USD Million (2013-2018)
  • Table 96. Netherlands Nanomedicine, by Type USD Million (2013-2018)
  • Table 97. Netherlands Nanomedicine, by Application USD Million (2013-2018)
  • Table 98. Netherlands Nanomedicine, by End Users USD Million (2013-2018)
  • Table 99. Netherlands Nanomedicine, by Modality USD Million (2013-2018)
  • Table 100. Rest of Europe Nanomedicine, by Type USD Million (2013-2018)
  • Table 101. Rest of Europe Nanomedicine, by Application USD Million (2013-2018)
  • Table 102. Rest of Europe Nanomedicine, by End Users USD Million (2013-2018)
  • Table 103. Rest of Europe Nanomedicine, by Modality USD Million (2013-2018)
  • Table 104. MEA Nanomedicine, by Country USD Million (2013-2018)
  • Table 105. MEA Nanomedicine, by Type USD Million (2013-2018)
  • Table 106. MEA Nanomedicine, by Application USD Million (2013-2018)
  • Table 107. MEA Nanomedicine, by End Users USD Million (2013-2018)
  • Table 108. MEA Nanomedicine, by Modality USD Million (2013-2018)
  • Table 109. Middle East Nanomedicine, by Type USD Million (2013-2018)
  • Table 110. Middle East Nanomedicine, by Application USD Million (2013-2018)
  • Table 111. Middle East Nanomedicine, by End Users USD Million (2013-2018)
  • Table 112. Middle East Nanomedicine, by Modality USD Million (2013-2018)
  • Table 113. Africa Nanomedicine, by Type USD Million (2013-2018)
  • Table 114. Africa Nanomedicine, by Application USD Million (2013-2018)
  • Table 115. Africa Nanomedicine, by End Users USD Million (2013-2018)
  • Table 116. Africa Nanomedicine, by Modality USD Million (2013-2018)
  • Table 117. North America Nanomedicine, by Country USD Million (2013-2018)
  • Table 118. North America Nanomedicine, by Type USD Million (2013-2018)
  • Table 119. North America Nanomedicine, by Application USD Million (2013-2018)
  • Table 120. North America Nanomedicine, by End Users USD Million (2013-2018)
  • Table 121. North America Nanomedicine, by Modality USD Million (2013-2018)
  • Table 122. United States Nanomedicine, by Type USD Million (2013-2018)
  • Table 123. United States Nanomedicine, by Application USD Million (2013-2018)
  • Table 124. United States Nanomedicine, by End Users USD Million (2013-2018)
  • Table 125. United States Nanomedicine, by Modality USD Million (2013-2018)
  • Table 126. Canada Nanomedicine, by Type USD Million (2013-2018)
  • Table 127. Canada Nanomedicine, by Application USD Million (2013-2018)
  • Table 128. Canada Nanomedicine, by End Users USD Million (2013-2018)
  • Table 129. Canada Nanomedicine, by Modality USD Million (2013-2018)
  • Table 130. Mexico Nanomedicine, by Type USD Million (2013-2018)
  • Table 131. Mexico Nanomedicine, by Application USD Million (2013-2018)
  • Table 132. Mexico Nanomedicine, by End Users USD Million (2013-2018)
  • Table 133. Mexico Nanomedicine, by Modality USD Million (2013-2018)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Nanomedicine: by Type(USD Million)
  • Table 145. Nanomedicine Liposomes , by Region USD Million (2019-2024)
  • Table 146. Nanomedicine Micelles , by Region USD Million (2019-2024)
  • Table 147. Nanomedicine Nanocrystals , by Region USD Million (2019-2024)
  • Table 148. Nanomedicine Polymeric Nanoparticles , by Region USD Million (2019-2024)
  • Table 149. Nanomedicine Metallic Nanoparticles , by Region USD Million (2019-2024)
  • Table 150. Nanomedicine Mesoporous Silica Nanoparticles , by Region USD Million (2019-2024)
  • Table 151. Nanomedicine Others , by Region USD Million (2019-2024)
  • Table 152. Nanomedicine: by Application(USD Million)
  • Table 153. Nanomedicine Drug Delivery , by Region USD Million (2019-2024)
  • Table 154. Nanomedicine Vaccines , by Region USD Million (2019-2024)
  • Table 155. Nanomedicine Diagnostic Imaging , by Region USD Million (2019-2024)
  • Table 156. Nanomedicine Regenerative Medicine , by Region USD Million (2019-2024)
  • Table 157. Nanomedicine Implants , by Region USD Million (2019-2024)
  • Table 158. Nanomedicine Others , by Region USD Million (2019-2024)
  • Table 159. Nanomedicine: by End Users(USD Million)
  • Table 160. Nanomedicine Hospitals , by Region USD Million (2019-2024)
  • Table 161. Nanomedicine Ambulatory Surgical Centre , by Region USD Million (2019-2024)
  • Table 162. Nanomedicine Clinics , by Region USD Million (2019-2024)
  • Table 163. Nanomedicine Specialised Drug R&D Institutes , by Region USD Million (2019-2024)
  • Table 164. Nanomedicine Managed Care Organizations , by Region USD Million (2019-2024)
  • Table 165. Nanomedicine: by Modality(USD Million)
  • Table 166. Nanomedicine Diagnostics , by Region USD Million (2019-2024)
  • Table 167. Nanomedicine Treatments , by Region USD Million (2019-2024)
  • Table 168. South America Nanomedicine, by Country USD Million (2019-2024)
  • Table 169. South America Nanomedicine, by Type USD Million (2019-2024)
  • Table 170. South America Nanomedicine, by Application USD Million (2019-2024)
  • Table 171. South America Nanomedicine, by End Users USD Million (2019-2024)
  • Table 172. South America Nanomedicine, by Modality USD Million (2019-2024)
  • Table 173. Brazil Nanomedicine, by Type USD Million (2019-2024)
  • Table 174. Brazil Nanomedicine, by Application USD Million (2019-2024)
  • Table 175. Brazil Nanomedicine, by End Users USD Million (2019-2024)
  • Table 176. Brazil Nanomedicine, by Modality USD Million (2019-2024)
  • Table 177. Argentina Nanomedicine, by Type USD Million (2019-2024)
  • Table 178. Argentina Nanomedicine, by Application USD Million (2019-2024)
  • Table 179. Argentina Nanomedicine, by End Users USD Million (2019-2024)
  • Table 180. Argentina Nanomedicine, by Modality USD Million (2019-2024)
  • Table 181. Rest of South America Nanomedicine, by Type USD Million (2019-2024)
  • Table 182. Rest of South America Nanomedicine, by Application USD Million (2019-2024)
  • Table 183. Rest of South America Nanomedicine, by End Users USD Million (2019-2024)
  • Table 184. Rest of South America Nanomedicine, by Modality USD Million (2019-2024)
  • Table 185. Asia Pacific Nanomedicine, by Country USD Million (2019-2024)
  • Table 186. Asia Pacific Nanomedicine, by Type USD Million (2019-2024)
  • Table 187. Asia Pacific Nanomedicine, by Application USD Million (2019-2024)
  • Table 188. Asia Pacific Nanomedicine, by End Users USD Million (2019-2024)
  • Table 189. Asia Pacific Nanomedicine, by Modality USD Million (2019-2024)
  • Table 190. China Nanomedicine, by Type USD Million (2019-2024)
  • Table 191. China Nanomedicine, by Application USD Million (2019-2024)
  • Table 192. China Nanomedicine, by End Users USD Million (2019-2024)
  • Table 193. China Nanomedicine, by Modality USD Million (2019-2024)
  • Table 194. Japan Nanomedicine, by Type USD Million (2019-2024)
  • Table 195. Japan Nanomedicine, by Application USD Million (2019-2024)
  • Table 196. Japan Nanomedicine, by End Users USD Million (2019-2024)
  • Table 197. Japan Nanomedicine, by Modality USD Million (2019-2024)
  • Table 198. India Nanomedicine, by Type USD Million (2019-2024)
  • Table 199. India Nanomedicine, by Application USD Million (2019-2024)
  • Table 200. India Nanomedicine, by End Users USD Million (2019-2024)
  • Table 201. India Nanomedicine, by Modality USD Million (2019-2024)
  • Table 202. South Korea Nanomedicine, by Type USD Million (2019-2024)
  • Table 203. South Korea Nanomedicine, by Application USD Million (2019-2024)
  • Table 204. South Korea Nanomedicine, by End Users USD Million (2019-2024)
  • Table 205. South Korea Nanomedicine, by Modality USD Million (2019-2024)
  • Table 206. Taiwan Nanomedicine, by Type USD Million (2019-2024)
  • Table 207. Taiwan Nanomedicine, by Application USD Million (2019-2024)
  • Table 208. Taiwan Nanomedicine, by End Users USD Million (2019-2024)
  • Table 209. Taiwan Nanomedicine, by Modality USD Million (2019-2024)
  • Table 210. Australia Nanomedicine, by Type USD Million (2019-2024)
  • Table 211. Australia Nanomedicine, by Application USD Million (2019-2024)
  • Table 212. Australia Nanomedicine, by End Users USD Million (2019-2024)
  • Table 213. Australia Nanomedicine, by Modality USD Million (2019-2024)
  • Table 214. Rest of Asia-Pacific Nanomedicine, by Type USD Million (2019-2024)
  • Table 215. Rest of Asia-Pacific Nanomedicine, by Application USD Million (2019-2024)
  • Table 216. Rest of Asia-Pacific Nanomedicine, by End Users USD Million (2019-2024)
  • Table 217. Rest of Asia-Pacific Nanomedicine, by Modality USD Million (2019-2024)
  • Table 218. Europe Nanomedicine, by Country USD Million (2019-2024)
  • Table 219. Europe Nanomedicine, by Type USD Million (2019-2024)
  • Table 220. Europe Nanomedicine, by Application USD Million (2019-2024)
  • Table 221. Europe Nanomedicine, by End Users USD Million (2019-2024)
  • Table 222. Europe Nanomedicine, by Modality USD Million (2019-2024)
  • Table 223. Germany Nanomedicine, by Type USD Million (2019-2024)
  • Table 224. Germany Nanomedicine, by Application USD Million (2019-2024)
  • Table 225. Germany Nanomedicine, by End Users USD Million (2019-2024)
  • Table 226. Germany Nanomedicine, by Modality USD Million (2019-2024)
  • Table 227. France Nanomedicine, by Type USD Million (2019-2024)
  • Table 228. France Nanomedicine, by Application USD Million (2019-2024)
  • Table 229. France Nanomedicine, by End Users USD Million (2019-2024)
  • Table 230. France Nanomedicine, by Modality USD Million (2019-2024)
  • Table 231. Italy Nanomedicine, by Type USD Million (2019-2024)
  • Table 232. Italy Nanomedicine, by Application USD Million (2019-2024)
  • Table 233. Italy Nanomedicine, by End Users USD Million (2019-2024)
  • Table 234. Italy Nanomedicine, by Modality USD Million (2019-2024)
  • Table 235. United Kingdom Nanomedicine, by Type USD Million (2019-2024)
  • Table 236. United Kingdom Nanomedicine, by Application USD Million (2019-2024)
  • Table 237. United Kingdom Nanomedicine, by End Users USD Million (2019-2024)
  • Table 238. United Kingdom Nanomedicine, by Modality USD Million (2019-2024)
  • Table 239. Netherlands Nanomedicine, by Type USD Million (2019-2024)
  • Table 240. Netherlands Nanomedicine, by Application USD Million (2019-2024)
  • Table 241. Netherlands Nanomedicine, by End Users USD Million (2019-2024)
  • Table 242. Netherlands Nanomedicine, by Modality USD Million (2019-2024)
  • Table 243. Rest of Europe Nanomedicine, by Type USD Million (2019-2024)
  • Table 244. Rest of Europe Nanomedicine, by Application USD Million (2019-2024)
  • Table 245. Rest of Europe Nanomedicine, by End Users USD Million (2019-2024)
  • Table 246. Rest of Europe Nanomedicine, by Modality USD Million (2019-2024)
  • Table 247. MEA Nanomedicine, by Country USD Million (2019-2024)
  • Table 248. MEA Nanomedicine, by Type USD Million (2019-2024)
  • Table 249. MEA Nanomedicine, by Application USD Million (2019-2024)
  • Table 250. MEA Nanomedicine, by End Users USD Million (2019-2024)
  • Table 251. MEA Nanomedicine, by Modality USD Million (2019-2024)
  • Table 252. Middle East Nanomedicine, by Type USD Million (2019-2024)
  • Table 253. Middle East Nanomedicine, by Application USD Million (2019-2024)
  • Table 254. Middle East Nanomedicine, by End Users USD Million (2019-2024)
  • Table 255. Middle East Nanomedicine, by Modality USD Million (2019-2024)
  • Table 256. Africa Nanomedicine, by Type USD Million (2019-2024)
  • Table 257. Africa Nanomedicine, by Application USD Million (2019-2024)
  • Table 258. Africa Nanomedicine, by End Users USD Million (2019-2024)
  • Table 259. Africa Nanomedicine, by Modality USD Million (2019-2024)
  • Table 260. North America Nanomedicine, by Country USD Million (2019-2024)
  • Table 261. North America Nanomedicine, by Type USD Million (2019-2024)
  • Table 262. North America Nanomedicine, by Application USD Million (2019-2024)
  • Table 263. North America Nanomedicine, by End Users USD Million (2019-2024)
  • Table 264. North America Nanomedicine, by Modality USD Million (2019-2024)
  • Table 265. United States Nanomedicine, by Type USD Million (2019-2024)
  • Table 266. United States Nanomedicine, by Application USD Million (2019-2024)
  • Table 267. United States Nanomedicine, by End Users USD Million (2019-2024)
  • Table 268. United States Nanomedicine, by Modality USD Million (2019-2024)
  • Table 269. Canada Nanomedicine, by Type USD Million (2019-2024)
  • Table 270. Canada Nanomedicine, by Application USD Million (2019-2024)
  • Table 271. Canada Nanomedicine, by End Users USD Million (2019-2024)
  • Table 272. Canada Nanomedicine, by Modality USD Million (2019-2024)
  • Table 273. Mexico Nanomedicine, by Type USD Million (2019-2024)
  • Table 274. Mexico Nanomedicine, by Application USD Million (2019-2024)
  • Table 275. Mexico Nanomedicine, by End Users USD Million (2019-2024)
  • Table 276. Mexico Nanomedicine, by Modality USD Million (2019-2024)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nanomedicine: by Type USD Million (2013-2018)
  • Figure 5. Global Nanomedicine: by Application USD Million (2013-2018)
  • Figure 6. Global Nanomedicine: by End Users USD Million (2013-2018)
  • Figure 7. Global Nanomedicine: by Modality USD Million (2013-2018)
  • Figure 8. South America Nanomedicine Share (%), by Country
  • Figure 9. Asia Pacific Nanomedicine Share (%), by Country
  • Figure 10. Europe Nanomedicine Share (%), by Country
  • Figure 11. MEA Nanomedicine Share (%), by Country
  • Figure 12. North America Nanomedicine Share (%), by Country
  • Figure 13. Global Nanomedicine share by Players 2018 (%)
  • Figure 14. Global Nanomedicine share by Players (Top 3) 2018(%)
  • Figure 15. Global Nanomedicine share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 18. GE Healthcare (United States) Revenue: by Geography 2018
  • Figure 19. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 21. Mallinckrodt plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Mallinckrodt plc (United Kingdom) Revenue: by Geography 2018
  • Figure 23. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co. Inc. (United States) Revenue: by Geography 2018
  • Figure 25. Nanosphere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Nanosphere Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2018
  • Figure 31. UCB (Union chimique belge) S.A (Belgium) Revenue, Net Income and Gross profit
  • Figure 32. UCB (Union chimique belge) S.A (Belgium) Revenue: by Geography 2018
  • Figure 33. Nanobiotix (France) Revenue, Net Income and Gross profit
  • Figure 34. Nanobiotix (France) Revenue: by Geography 2018
  • Figure 35. Nanomedical systems (United States) Revenue, Net Income and Gross profit
  • Figure 36. Nanomedical systems (United States) Revenue: by Geography 2018
  • Figure 37. Global Nanomedicine: by Type USD Million (2019-2024)
  • Figure 38. Global Nanomedicine: by Application USD Million (2019-2024)
  • Figure 39. Global Nanomedicine: by End Users USD Million (2019-2024)
  • Figure 40. Global Nanomedicine: by Modality USD Million (2019-2024)
  • Figure 41. South America Nanomedicine Share (%), by Country
  • Figure 42. Asia Pacific Nanomedicine Share (%), by Country
  • Figure 43. Europe Nanomedicine Share (%), by Country
  • Figure 44. MEA Nanomedicine Share (%), by Country
  • Figure 45. North America Nanomedicine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GE Healthcare (United States)
  • Johnson & Johnson (United States)
  • Mallinckrodt plc (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Nanosphere Inc. (United States)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UCB (Union chimique belge) S.A (Belgium)
  • Nanobiotix (France)
  • Nanomedical systems (United States)
Additional players considered in the study are as follows:
Sigma-Tau Pharmaceuticals Inc. (United Kingdom) , Smith & Nephew PLC (United Kingdom) , Stryker Corp (United States) ,
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation